Skip to main content
European Commission logo print header
Zawartość zarchiwizowana w dniu 2022-12-23

European Concerted Action on Prevention from Thrombosis by Urokkinase Enhancement

Cel



In most developed countries cardiovascular diseases are one the leading causes of death in humans after age 45. As a rule, thrombotic occlusion occurs in the arterial part of the vascular net. It is necessary to develop a universal form of prophylaxis that would accomplish a general delay of the fatal, mainly arterial occluding thrombosis. Our proposed project is a part of the 'European Concerted Action on Prevention from Thrombosis by rokinase Enhancement' (ECAPTURE). ECAPTURE aims at prophylaxis by reinforcing the natural defence mechanism against thrombosis, i.e. the vascular fibrinolysis, specifically by chronic pharmacological enhancement of the endogenous level of single-chain urokinase-type plasminogen activator (scu-PA).
Our project as a part of the ECAPTURE aims to assess the efficacy of scu-PA in the prevention of arterial thrombosis and to determine the mechanisms of scu-PA prophylactic antithrombotic action.Wwe hypothesize that t-PA plays the main role in prevention and lysis of fibrinrich venous thrombi, but scu-PA is mainly responsible for the prevention and lysis of platelet-rich arterial thrombi. Reinforcing of the humoral fibrinolysis by scu-PA administration or enhancement could efficiently prevent an arising of the arterial platelet-dependent thrombosis or induce a rapid dissolution of these thrombi.
In this way we expect to compensate the altered vascular fibrinolysis caused by the defective t-PA release and to prevent or delay the fatal, occluding arterial thrombosis.For a resolution of the proposed objectives in each main part of work the experiments in vitro and in vivo will be conducted.
These experiments are directed on the solution of question about feasibility and mechanisms of prevention of the arterial, platelet-rich thrombosis by the subthrombolytic doses of scu-PA in blood. Two main problems will be studied: 1) prophylaxis of thrombosis, and 2) the influence of scu-PA on the growth of the preformed thrombi. The solution of this problem allows to develop a novel approach of prevention from the predominant type of thrombosis in human, i.e.aterial thrombosis.

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek
Wkład UE
Brak danych
Adres
9,Zernikedreef
2301 CE Leiden
Niderlandy

Zobacz na mapie

Koszt całkowity
Brak danych

Uczestnicy (1)